Bravinton - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Has vasodilator, antihypoxic and antiaggregatory action. It inhibits phosphodiesterase and increases the content of cyclic adenosine monophosphate in cells, which in turn leads to a decrease in calcium content in the cytoplasm of smooth muscle cells and relaxation of myofibrils.It combines vascular and metabolic actions. It dilates the blood vessels of the brain, increases blood flow, improves the supply of oxygen to the brain. Promotes the utilization of glucose and increases the level of catecholamines in the central nervous system, stimulates the metabolism of norepinephrine and serotonin in the brain tissues. Reduces platelet aggregation, blood viscosity, promotes increased erythrocyte deformability and normalization of venous outflow against a background of decreased resistance of cerebral vessels. Systemic blood pressure slightly decreases. In the elderly and senile age, the sensitivity of cerebral vessels to the action of vinpocetin increases, which is due to the sensitization of the adenylate cyclase system - cyclic adenosine monophosphate upon aging.

Pharmacokinetics:

Easily penetrates through gistogematicheskie barriers (including through the blood-brain barrier). The volume of distribution is 5.3 l / kg body weight. The half-life is 4.74 hours.

Indications:

- acute and chronic forms of cerebral circulation insufficiency (acute and recovery stages of ischemic stroke, recovery stage of hemorrhagic stroke, transient ischemic attack, encephalopathy, multi-infarct dementia);

- in ophthalmology: in vascular diseases of the retina and / or choroid of the eye; with degenerative changes of the yellow spot caused by atherosclerosis or angiospasm; with partial occlusion of vessels, secondary glaucoma;

- in otolaryngology with senile hearing loss, Meniere's disease, hearing loss of vascular or toxic (including medicamentous) genesis, with dizziness of labyrinth origin.

Contraindications:

Hypersensitivity; severe ischemic heart disease; severe cardiac rhythm disturbances; acute phase of hemorrhagic stroke; pregnancy and lactation, children under 18 years of age.

Dosing and Administration:

Intravenously drip. 20 mg is diluted in 250-400 ml of the infusion solution. With good tolerability, the dose of the drug is increased to 1 mg / kg for 3-4 days, treatment is continued for 10-14 days. After completing the course of parenteral administration, they switch to oral administration of the drug. Before cancellation, the drug should be gradually reduced.

Side effects:

Dizziness, a feeling of heat, hyperemia of the facial skin, nausea, thrombophlebitis at the injection site.From the side of the cardiovascular system, transient decrease in arterial pressure, tachycardia, extrasystole, an increase in the time of excitation of the ventricles, thrombophlebitis at the site of administration can be observed.

Interaction:

Increases the risk of hemorrhagic complications against heparin therapy. Pharmaceutically incompatible with heparin.

Special instructions:

When parenteral administration of patients with diabetes mellitus should monitor the blood glucose, because in the solution is contained sorbitol.

Form release / dosage:

Concentrate for the preparation of solution for infusions 5 mg / ml.

Packaging:

2 ml in ampoules of light-protective glass. By 5 ampoules in a planar cell packaging made of a polyvinylchloride film and aluminum foil or a packaging or uncoated material. 1 or 2 contour packs together with instructions for use and a vial for opening ampoules or a scarifier ampoule - in a pack of cardboard. 5 or 10 ampoules together with instructions for use and a vial for opening ampoules or a scarifier ampoule - in a pack of cardboard with an insert with cells for ampoules in 1 or 2 rows.When using ampoules with notches, the ampoule knife or scarifier does not enclose the fracture ring.

Storage conditions:

List B. In the dark place at a temperature of no higher than 25 ° C.

Shelf life:

2 years.

Do not use after the time specified on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000345 / 01

Date of registration:13.10.2008 / 03.12.2015

Expiration Date:Unlimited

The owner of the registration certificate:BRYNTSALOV-A, CJSC BRYNTSALOV-A, CJSC Russia

Manufacturer: & nbsp

BRYNTSALOV-A, CJSC Russia

Information update date: & nbsp21.02.2017

Illustrated instructions

Instructions

Bravinton® (Bravintone)